A Pilot Clinical Study to Evidence Safety and Efficacy of Fracture Fixation of the Distal Radius … (NCT07452536) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Pilot Clinical Study to Evidence Safety and Efficacy of Fracture Fixation of the Distal Radius Using a Bioresorbable Bone Adhesive to Augment Metal Hardware
20 participantsStarted 2026-04-15
Plain-language summary
A prospective, multi-center (up to 4 sites), single-arm, study of 20 subjects. Patient enrollment will consist of subjects with an AO/OTA type 2R3C distal radius fracture. Enrollment will be prospectively stratified based on patient age (Stratum A: \<65 and Stratum B: ≥65 years)
Who can participate
Age range21 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Unilateral, unstable and/or displaced distal radius AO/OTA type 2R3C fracture.
* Standard treatment would consist of open reduction internal fixation (ORIF) with plate(s) and screws using a volar approach
* Surgical visit occurs within 2 weeks of injury.
* No radiographic evidence of fracture healing prior to surgical treatment.
* Male or female, greater than 21 years of age
* Subject living independently and ambulatory at the time of injury.
* Subject, and/or subject's representatives are able and willing to provide informed consent and HIPAA authorization.
* Subject able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests.
Intra-Operative Inclusion Criteria:
* No sign of active infection at the planned operative site.
* Surgeons will decide whether the fracture site is a good candidate for TN-MFF use once the site is open and they can visualize the bone and surrounding soft tissue.
Exclusion Criteria:
* Significant ligamentous disruption requiring independent repair
* Other fractures of the carpal bones or injured limb (Note: an associated ulnar styloid fracture is not exclusionary)
* Pathological fracture related to an underlying malignancy
* Open fractures
* A previous fracture in the injured bone within the last 12 months
* Presence of other orthopaedic implant in the injured bone
* Patients with presumptive diagnosis of named nerve or blood vessel injury
* Current in…
What they're measuring
1
Safety based on the rate of serious device related adverse events
Timeframe: For 52 weeks following surgery
2
Efficacy based on the fracture union assessment at the 26-week follow-up
Timeframe: 26 weeks
3
Efficacy based on the DASH assessment at the 26-week timepoint